A New Approach
To Cell Therapy
Like elite athletes training at high elevation, T cells conditioned in challenging environments develop the attributes needed to outperform in solid tumors
The Challenge: Overcoming The Hostile TME
While having success in heme indications, CAR-T therapies have thus far been lacking durable responses in solid tumors, which represent 90% of cancer cases.
Solid tumors are protected by a hostile tumor microenvironment (TME), which stifles T cell responses through metabolic stress, immunosuppression, and exhaustion
The Solution: OUTLASTTM -Metabolically Reprogramming T Cells To Thrive in the TME
OUTLAST™ replicates the harsh conditions of the TME during cell manufacturing to reprogram T cells to outperform in solid tumors.
OUTLAST™ reprogrammed T cells exhibit enhanced persistence, metabolic fitness, and resistance to exhaustion – key attributes for cell therapy success in solid tumors.
Resist Exhaustion
OUTLASTTM CAR T cells exhibit superior activation and resist exhaustion even after long term activity in vivo in an aggressive solid tumor model.
Enhance Durability
OUTLASTTM upregulates genes associated with long lives, persistent, stem-like early memory cells.
Retain Function
OUTLASTTM suppresses genes associates with short-lived, terminally differentiated effector cells and T cell exhaustion.
Stay Up to Date on Inceptor
Inceptor Bio to Present IB-T101 Data at the 2025 SITC Annual Meeting
Morrisville, NC — Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies to cure cancer, announced today that it
Inceptor Bio to Present IB-T101 and OUTLAST™ Platform at ASCO 2025
Morrisville, NC – Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies to cure cancer, announced today that it
Inceptor Bio to Present at AACR 2025: Spotlight on IB-T101 and the OUTLAST™ Platform
Morrisville, NC – Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies to cure cancer, today announced that it
